Scientists Discover Hidden Backup System in Human Kidneys

Mayo Clinic researchers have identified a new kidney pathway for water regulation that functions independently of the hormone vasopressin. Led by nephrologist Fouad Chebib, M.D., the study published in the Journal of Clinical Investigation suggests this mechanism could help manage polycystic kidney disease (PKD) by reducing the excessive urination currently caused by standard treatments.

How does the new kidney water regulation pathway work?

For decades, scientists believed the body’s ability to concentrate urine and prevent dehydration relied almost entirely on the hormone vasopressin. This new research shows the kidneys possess an additional, independent mechanism for regulating water.

The discovery involves how kidney cells handle urate, a molecule often linked to gout. According to Dr. Chebib, when probenecid—a medication used to alter urate levels—is present, it triggers urate to act as a signaling molecule inside kidney cells. This signal moves water channels to the cell surface, allowing the kidneys to reabsorb water and concentrate urine without needing vasopressin.

“This represents a distinct pathway from what is described in traditional physiology models,” Dr. Chebib told the researchers. He noted that the discovery proves the kidney has a secondary way to preserve water.

Why is this discovery significant for polycystic kidney disease (PKD) patients?

Polycystic kidney disease is a genetic disorder where fluid-filled cysts grow in the kidneys. These cysts eventually impair function and can lead to kidney failure. In the United States, approximately 140,000 people live with the most common form, autosomal dominant PKD (ADPKD).

Currently, the only approved medication to slow the progression of PKD is tolvaptan. While effective, the drug works by blocking vasopressin. This creates a significant side effect: patients often produce massive amounts of urine, sometimes between 6 and 7 liters per day. This frequent urination can be difficult to manage and leads many patients to stop their treatment entirely.

The Mayo Clinic study suggests that targeting this newly discovered urate pathway could offer a way to slow cyst growth without the heavy burden of extreme thirst and urination.

Can probenecid reduce the side effects of current PKD treatments?

In preclinical studies and a small clinical trial, researchers tested the effects of adding probenecid to existing treatment protocols. The results showed a clear benefit in managing urine volume while maintaining therapeutic effectiveness.

The following data highlights the potential impact of combining these treatments:

“The goal is to preserve the therapeutic benefit of tolvaptan while reducing its burden,” Dr. Chebib said.

What happens next in PKD research?

While the results are promising, the research team isn’t looking to use probenecid as a permanent solution. Because the drug is decades old and affects multiple biological systems, it isn’t the ideal long-term candidate for specialized PKD therapy.

Instead, the team plans to use this discovery as a blueprint. By understanding how the urate signaling pathway works, they aim to develop new, targeted therapies that specifically activate this water-conservation mechanism without the widespread systemic effects of older medications.

For Dr. Chebib, the work is also personal. His interest in kidney disease began after his father was diagnosed with PKD, a journey he describes as deeply purposeful.

Want to stay updated on the latest medical breakthroughs? Subscribe to our newsletter or leave a comment below with your thoughts on this discovery.